Hydroxycarbamide - Addmedica

Drug Profile

Hydroxycarbamide - Addmedica

Alternative Names: Hydroxyurea - Addmedica; NSC-32065; Onco-carbide; Siklos; SQ-1089

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProStrakan
  • Developer addmedica
  • Class Antianaemics; Antineoplastics; Small molecules; Urea compounds
  • Mechanism of Action DNA synthesis inhibitors; Fetal haemoglobin stimulants; Nitric oxide stimulants; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Sickle cell anaemia

Most Recent Events

  • 15 Mar 2018 Medunik USA receives marketing license for Hydoxycarbamide in USA, prior to March 2018
  • 21 Dec 2017 Registered for Sickle cell anaemia (In adolescents, In adults, In children, Prevention) in USA (PO)
  • 21 Dec 2017 Hydroxycarbamide receives priority review status for Sickle cell anaemia (In adolescents, In adults, In children, Prevention) in USA (PO) before December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top